Zobrazeno 1 - 10
of 108
pro vyhledávání: ''
Publikováno v:
Cardiovascular Drugs and Therapy. 36:829-840
Ticagrelor and dapagliflozin can suppress the activation of the NOD-like receptor 3 (NLRP3)-inflammasome and activate AMP-activated protein kinase (AMPK). The anti-inflammatory effects of dapagliflozin has been shown to depend on AMPK activation. Dap
Autor:
Yue Wang, Hong-feng Jiang, Hai-ming Dang, Meng-ru Liu, Xin-yan Liu, Yang Yu, Jiang Xie, Xiao-jun Zhan, Hui-na Zhang, Xiao-fan Wu
Publikováno v:
Cardiovascular Drugs and Therapy. 36:805-815
It has been established that obstructive sleep apnea (OSA) is an independent risk factor for atherosclerosis. Chronic intermittent hypoxia (CIH) activates sympathoadrenal system and upregulates β3 adrenergic receptor (β3 AR). However, the effect of
Publikováno v:
Cardiovascular Drugs and Therapy. 33:45-54
Myocardial ischemia/reperfusion (I/R) injury is a serious threat to the health of people around the world. Recent evidence has indicated that high-mobility group box-1 (HMGB1) is involved in I/R-induced inflammation, and inflammation can cause necrop
Publikováno v:
Cardiovascular drugs and therapy. 35(1)
Attenuated vasodilatation of small arteries is a hallmark feature of hypertension. Salusin-β, which is a TOR2A gene product and an important vasoactive peptide, has a close relationship with cardiovascular disease. This study aimed to determinate th
Publikováno v:
Cardiovascular Drugs and Therapy. 32:135-145
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and dipeptidyl peptidase-4 inhibitors (DPP4I) are used to treat type 2 diabetes (T2DM). DPP4 inhibitors (DPP4) attenuate Nlrp3 inflammasome activation in the kidney. SGLT2 inhibition reduces inflammat
Autor:
Tiziana Bacchetti, Željko Reiner, Gianna Ferretti, Luis E. Simental-Mendía, Amirhossein Sahebkar, Maciej Banach
Publikováno v:
Cardiovascular drugs and therapy. 31(2)
Lipoprotein(a) (Lp(a)) is a proatherogenic plasma lipoprotein and an independent risk factor for atherosclerotic cardiovascular disease. We investigated the effects of raloxifene, selective estrogen receptor modulator, on circulating Lp(a) levels in
Autor:
Jing Yang, Yingguang Shan, Dandan Wang, Ran Li, Yuting Chen, Yanhong Tang, Yan Huang, Congxin Huang
Publikováno v:
Cardiovascular drugs and therapy. 30(5)
Chronically elevated catecholamine levels activate cardiac β-adrenergic receptors, which play a vital role in the pathogenesis of heart failure. Evidence suggests that vasostatin-1 (VS-1) exerts anti-adrenergic effects on isolated and perfused heart
Autor:
Alkistis Kapelouzou, Christos D. Liapis, Petros Moustardas, Katrin Schäfer, Alkiviadis Kostakis, Michael Katsimpoulas, Nikolaos Kostomitsopoulos, Nikolaos P.E. Kadoglou
Publikováno v:
Cardiovascular Drugs and Therapy. 26:367-374
Dabigatran etexilate (DE) constitutes a novel, direct thrombin inhibitor. Regarding the association of thrombin with atherogenesis, we assessed the effects of DE on the development and stability of atherosclerotic lesions in apolipoprotein-E deficien
Autor:
Mauro Contini, Pietro Palermo, Gaia Cattadori, Cesare Fiorentini, Anna Apostolo, Elena Tremoli, Stefania Farina, Elisa Compagnino, Marina Camera, Damiano Magrì, Piergiuseppe Agostoni, Karl Gertow
Publikováno v:
Cardiovascular drugs and therapy. 30(2)
The benefit of angiotensin converting enzyme (ACE) inhibition in chronic heart failure (HF) is partially due to its effects on pulmonary function and particularly on lung diffusion, the latter being counteracted by acetylsalicylic acid (ASA). Tissue
Publikováno v:
Cardiovascular Drugs and Therapy. 25:77-82
The aim of this study was to evaluate the therapeutic efficacy of tolvaptan, a vasopressin V(2) receptor antagonist, on edema in two rat models: 1) histamine-induced vascular hyperpermeability of the dorsal skin and 2) carrageenan-induced paw edema.I